Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel Anti-CD47 Nanobody Tetramer for Cancer Therapy

2 Jan 2024

Abstract excerpt

CD47 acts as a defense mechanism for tumor cells by sending a "don't eat me" signal via its bond with SIRPα. With CD47's overexpression linked to poor cancer outcomes, its pathway has become a target in cancer immunotherapy. Though monoclonal antibodies offer specificity, they have limitations like the large size and production costs. Nanobodies, due to their small size and unique properties, present a promising...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement system in diseases
Share to Monoclonal and Polyclonal Antibodies Research
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38247566
DOI: 10.3390/antib13010002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel Anti-CD47 Nanobody Tetramer for Cancer TherapyPMID 38247566Read ↗

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα AxisSemantic proximity Read ↗

Recent Advances of Tumor Therapy Based on the CD47-SIRPα AxisSemantic proximity Read ↗

Breaking the ‘Don’t Eat Me’ Signal: In Silico Design of CD47 Directed Peptides for Cancer ImmunotherapySemantic proximity Read ↗

Blockade of CD47 or SIRPα: a new cancer immunotherapySemantic proximity Read ↗

Targeting CD47: the achievements and concerns of current studies on cancer immunotherapySemantic proximity Read ↗

Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell MetastasisSemantic proximity Read ↗

A Homogeneous SIRPα-CD47 Cell-Based, Ligand-Binding Assay: Utility for Small Molecule Drug Development in Immuno-oncologySemantic proximity Read ↗

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunitySemantic proximity Read ↗

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpointSemantic proximity Read ↗

The CD47-SIRP signalling system: its physiological roles and therapeutic applicationSemantic proximity Read ↗

Programmable bacteria induce durable tumor regression and systemic antitumor immunitySemantic proximity Read ↗

Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.